LSTA

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2003, for Corniche Group Incorporated. The company discontinued its primary business of selling extended warranties and service contracts in June 2002 due to operating losses. Current operations consist of the "run-off" of prior warranty contracts and the exploration of a new business plan in the medical/biotech sector under the name "Phase III Medical, Inc." The company has appointed Mark Weinreb as President and CEO to execute this new strategy. Management has raised substantial doubt about the company's ability to continue as a going concern due to a lack of operations and available means to finance current expenses.

Key Financial Metrics

Debt and Liquidity: The company holds $1,000,000 in notes receivable from StrandTek International (net of a $250,000 allowance). Total debt includes $185,000 in notes payable and $26,642 in long-term bank debt. Current liabilities exceed current assets by approximately $234,000.

Material Changes vs. Prior Period

• Revenue Decline: Earned revenues decreased by approximately 27% to $18,004, derived entirely from the amortization of deferred revenues from prior warranty contracts.
• Expense Reduction: General and administrative expenses dropped significantly by 65.4% (from $371,435 to $128,578), driven by reductions in legal fees, payroll, and IT costs associated with the discontinued warranty business.
• Net Loss Improvement: The net loss decreased by 56.7% to $142,980 compared to $329,842 in the prior year, primarily due to lower operating expenses.
• Interest Income Collapse: Interest income fell by $41,016 to $4, as the company no longer earns interest on the defaulted StrandTek loans or marketable securities.
• Interest Expense Increase: Interest expense rose to $19,487 from $1,119 due to new short-term promissory notes issued in late 2002.

Outlook, Risks, and Contingencies

• Going Concern Uncertainty: The filing explicitly states that the company has no operations or means to finance current expenses, raising substantial doubt about its ability to continue as a going concern.
• Capital Raising: The company is actively seeking new capital through private placements of promissory notes (up to $250,000) and equity to fund the new medical sector business plan. Success is not assured.
• Legal Contingency (StrandTek): The company obtained a final summary judgment against StrandTek International and four individual guarantors for approximately $1.42 million. However, StrandTek filed for an assignment for the benefit of creditors, making collection from the corporate entity highly unlikely. Recovery depends entirely on the personal guarantees of the individual defendants.
• Debt Deferral: The company entered into a deferment agreement with three major creditors to delay payment of approximately $524,000 in liabilities until January 2005, contingent on successful financing.
• Stock Options: Significant stock options were granted to the new CEO (2.5 million shares at $0.03) with potential for additional grants if stock price targets are met.

Investor Verification Checklist

• Cash Runway: Verify if the $14,877 cash balance is sufficient to cover immediate obligations given the $1.3 million in current liabilities.
• StrandTek Collection: Assess the likelihood of collecting the $250,000 guaranteed portion of the judgment from the individual defendants versus the unsecured corporate portion.
• Financing Progress: Confirm the status of the private placement offerings for promissory notes and whether the $250,000 target was met.
• Debt Default Risk: Review the terms of the 60-day and 30-day promissory notes issued in 2002 and 2003 to determine if default penalties (conversion to equity) are imminent.
• Going Concern Status: Evaluate the feasibility of the "Phase III Medical" pivot given the lack of current revenue generation and the need for significant new capital.